KALRAY
6.6.2023 17:47:27 CEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets from cloud to edge today announces the tape-out1 of Coolidge™2, a new version of its 3rd generation Coolidge™ DPU processor. Based on Kalray’s patented MPPA® (Massively Parallel Processor Array) architecture, the Coolidge™2 processor has been designed to deliver ever-higher performance in the processing of artificial intelligence (AI) and data in general. Thanks to Coolidge™2, Kalray intends to accelerate its growth, particularly in edge computing and data- intensive storage workloads.
COOLIDGE™2, AN ULTRA-HIGH-PERFORMANCE DPU PROCESSOR FOR AI
At a time when AI development is progressing rapidly, mastering this technology is a major challenge, both in terms of managing algorithms and in processing the massive quantities of data generated and stored by AI workloads. Processors are at the forefront of the solution.
“We are very excited to announce the tape-out of Coolidge™2, in line with our roadmap. This is an essential milestone, marking the start of the manufacturing process and the culmination of a technological challenge. Coolidge™2 will enable us to offer enterprises an extremely competitive alternative for data processing and AI in particular, with one of the best ratios for performance/energy consumption/price in the inference and edge computing markets “, says Eric Baissus, CEO of Kalray.
In this race to performance, Kalray’s Coolidge™2 DPU processor stands out for its MPPA® architecture, which offers unique capabilities and enables fine control over neural network processing, from memory transfers to utilization of the processor’s computing capabilities. Kalray has optimized every element to enhance the processor’s overall performance, demonstrating the effectiveness of the Coolidge™2 processor architecture.
As a result, Coolidge™2 will offer up to 10 times the performance as compared to the previous version of the processor. This improvement will be relevant for applications such as deep learning algorithms used in neural networks applied to image processing.
At the end of 2022, Kalray announced the signing of a "jumbo contract2" with a major player, who intends to integrate Coolidge™2 into its forthcoming solutions.
SOLUTIONS FOR DATA-INTENSIVE STORAGE
With the rise of AI and the need to process and analyze data ever more efficiently, fast storage plays an essential role. Large language model solutions such as ChatGPT could not function without a fast, efficient storage system that enables predictive models to be trained as quickly as possible.
Thanks to its DPU processor, Kalray enjoys a unique position in the data-intensive storage market. Coolidge™2 is specifically optimized to complement Kalray's current range of NVMe storage solutions and to deliver the performance required to meet market demands for years to come.
“Data-intensive storage is a fast-growing market, particularly due to the adoption of increasingly large predictive AI models that are very greedy for storage resources during the learning phases. Coolidge™2 offers our customers a unique solution to accelerate the learning phase of models, which is a major challenge for the industry,” concludes Eric Baissus.
Finally, Coolidge™2 will provide all the technical assets of its predecessor: computing power combined with low energy consumption, ease of programming, high-speed interfaces, the ability to run multiple applications in parallel and deterministically, and on-the-fly, real-time data processing. The first samples of Coolidge™2 will be available this summer.
A FAST-GROWING DEEP TECH COMPANY WITH HIGH AMBITIONS
Today, Kalray is the only European player to offer this new-generation, high-performance, low-power DPU processor.
The company is positioning itself to become a key player in the data processing market in the years to come. With the acquisition in 2022 of Arcapix Holdings Ltd, a software company specializing in data storage and management solutions, Kalray has complemented its hardware offerings with software solutions, enabling it to offer a complete range of products and services. Current partnerships with leading technology vendors such as Dell Technologies, a partnership from which Kalray is beginning to reap the first results, demonstrate the relevance of its value proposition and offering.
Product offerings, customer portfolio, sales growth and workforce expansion: Kalray is undergoing a rapid transformation at every level of the company. While many tech players have massively downsized, Kalray's headcount has jumped by 74% in one year, and is set to grow by another 20% in 2023 to keep pace with the company’s development efforts.
Alongside Coolidge™2, Kalray's teams are preparing for the future and are already working on Kalray's 4th generation DPU processor, Dolomites™.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
___________________________
1 The Tape-out is an important stage in the life cycle of a processor, marking the completion of the design phase and the start of the manufacturing process with the sending of the photomask graphics of the circuits to the manufacturing plant.
2See press release, November 14, 2022, “Signing of a Large Contract with an Industry Leader for Kalray's DPU Processor”.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005623/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
